Myriad (MYGN) Issues Response to Supreme Court Decision on Gene Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
Jefferies Stays on Sidelines with Myriad (MYGN) after DNA Ruling
June 14, 2013 7:57 AM EDTJefferies reiterated a Hold rating and $31 price target on Myriad Genetics (NASDAQ: MYGN) Friday following yesterday's US Supreme Court ruling that the company's human isolated DNA patent claims are invalid, while its synthetic DNA (cDNA) claims are patent eligible.
"While the court's... More
BofA/Merrill Lynch Downgrades Myriad Genetics (MYGN) to Neutral
June 14, 2013 6:46 AM EDTBofA/Merrill Lynch downgraded Myriad Genetics (NASDAQ: MYGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $32.01 yesterday, with a 52 week range of $22.02-$38.27.... More
RBC Capital Downgrades Myriad Genetics (MYGN) to Sector Perform
June 14, 2013 6:45 AM EDTRBC Capital downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Sector Perform with a price target of $32.00 (unchanged).
For an analyst ratings summary and ratings history on Myriad Genetics click here. For... More
JMP Securities Upgrades Myriad Genetics (MYGN) to Market Outperform
June 14, 2013 6:44 AM EDTJMP Securities upgraded Myriad Genetics (NASDAQ: MYGN) from Market Perform to Market Outperform with a price target of $48.00.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For... More
Leerink Swann Downgrades Myriad Genetics (MYGN) to Market Perform
June 13, 2013 2:44 PM EDTLeerink Swann downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform with a price target of $39.00. Analyst Dan Leonard thinks investor focus will now turn to competition and the stock has no place to go but down.
"Following the Supreme Court's... More
Piper Jaffray Boosts Myriad Genetics (MYGN) Price Target to $49
June 13, 2013 1:50 PM EDTPiper Jaffray today maintained an Overweight rating on Myriad Genetics (NASDAQ: MYGN) and raised its price target to a Street-high $49.00 (from $39.00).
For an analyst ratings summary and ratings history on Myriad Genetics click... More
Myriad Genetics (MYGN) trading paused/halted due to limit up, limit down
June 13, 2013 10:26 AM EDTMyriad Genetics, Inc. (NASDAQ: MYGN) trading paused due to limit up, limit down.... More
Gene Patent Limited by High Court in Mixed Ruling for Myriad (MYGN)
June 13, 2013 10:24 AM EDT(Updated - June 13, 2013 10:33 AM EDT)
Gene patent limited by high court in mixed ruling for Myriad Genetics, Inc. (NASDAQ: MYGN), according to Bloomberg headlines.
For the U.S. Supreme Court document (pdf format), click here.
Myriad is up 9 percent on the session.... More
